Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Metastatic malignant disease of unknown primary origin in adults: diagnosis and management

Clinical guideline
Reference number: CG104
Published: 26 July 2010
Last updated: 26 April 2023

Register as a stakeholder

History

Review documents

Static list review decision (PDF 1.38 MB)

Published:

17 February 2014

Other information

Evidence update (PDF 227 KB)

Published:

01 February 2012

Remit

Remit (PDF 41 KB)

Published:

14 August 2008

Scoping workshop, consultation and final scope

Scoping workshop, consultation and final scope
Scope consultation - stakeholder comments & NCC responses (PDF 62 KB)

Published:

15 May 2008
Scope consultation information
Draft scope (PDF 40 KB)

Published:

21 January 2008
List of registered stakeholders (PDF 26 KB)

Published:

09 June 2010

Guideline development and consultation

Guideline development and consultation
GDG membership list (PDF 17 KB)

Published:

02 March 2009
Minutes for GDG meetings
GDG minutes 5th & 6th October 2009 (PDF 18 KB)

Published:

21 May 2010
GDG minutes 8 September 2009 (PDF 19 KB)

Published:

23 October 2009
GDG minutes 21 July 2009 (PDF 18 KB)

Published:

07 December 2009
GDG minutes 8 May 2009 (PDF 18 KB)

Published:

24 June 2009
GDG minutes 24 March 2009 (PDF 18 KB)

Published:

17 July 2009
GDG minutes 5 February 2009 (PDF 19 KB)

Published:

31 March 2009
GDG minutes 17 December 2008 (PDF 21 KB)

Published:

24 June 2009
GDG minutes 20 October 2008 (PDF 18 KB)

Published:

03 February 2009
GDG minutes 5 September 2008 (PDF 19 KB)

Published:

24 June 2009
GDG minutes 18 July 2008 (PDF 18 KB)

Published:

24 June 2009
GDG minutes 10 June 2008 (PDF 21 KB)

Published:

21 August 2008
GDG minutes 8 May 2008 (PDF 19 KB)

Published:

26 June 2008
Guideline consultation information
Full guideline (PDF 1.05 MB)

Published:

02 December 2009
NICE guideline (PDF 144 KB)

Published:

02 December 2009
Evidence review (PDF 3.24 MB)

Published:

02 December 2009
Comments proforma (MSWord 54 KB)

Published:

02 December 2009
registered stakeholder organisation (PDF 19 KB)

Published:

05 July 2012
Invitation to patients, family and carers for views on experiences of metastatic malignant disease of unknown primary origin information
Invitation to patients, family and carers for views on experiences of metastatic malignant disease of unknown primary origin: letter of invitation (MSWord 116 KB)

Published:

22 April 2009
EIA form (MSWord 78 KB)

Published:

09 November 2010

Pre-publication check

Pre-publication check information
Pre-publication check - stakeholder comments/developer responses (PDF 19 KB)

Published:

26 July 2010
Pre-publication check - full guideline (PDF 1.1 MB)

Published:

17 May 2010
Pre-publication check - evidence review for full guideline (PDF 4.97 MB)

Published:

17 May 2010
Draft guideline consultation - stakeholder comments and responses (PDF 491 KB)

Published:

16 August 2011
Pre-publication check - pre-publication comments form (MSWord 48 KB)

Published:

17 May 2010